**Core tip:** Immunohistochemical detection of p53, carcinoembryonic antigen (CEA) and CA19-9 proteins was carried out in patients with basal cell hyperplasia, low-grade dysplasia, high-grade dysplasia, invasive cancer, and normal controls from an area with a high incidence of esophageal lesions. Our data suggest that p53, CEA, and CA19-9 protein expression correlated with the stages of esophageal carcinogenesis. In an endoscopic screening program, the expression of these three biomarkers will be a useful panel for identifying high-risk patients with precancerous lesions, and the results will provide a basis for targeted prevention in a high-incidence area of esophageal carcinoma.

INTRODUCTION
============

Esophageal squamous cell carcinoma (ESCC) is one of the most lethal malignancies\[[@B1]\]. Due to the lack of effective clinical methods for early detection, most patients are at an advanced stage at the time of diagnosis\[[@B2]-[@B4]\]. ESCC is the fourth most common cause of cancer death in China\[[@B5],[@B6]\].

The pathogenesis of ESCC involves a stepwise progression from basal cell hyperplasia (BCH) to low-grade dysplasia (LGD), high-grade dysplasia (HGD), carcinoma *in situ*, and finally invasive carcinoma. Esophageal dysplasia is a precancerous lesion\[[@B7]-[@B11]\], but the development from dysplasia to carcinoma is by no means inevitable\[[@B12]\]. Long-term epidemiological studies have indicated that severe-dysplasia is related to the risk of ESCC development, but LGD transforms into HGD only in a small number of patients, and can revert to normal mucosa or does not transform into malignant lesions in the majority of patients\[[@B13]-[@B16]\].

Endoscopic screening is effective in early esophageal cancer and to ascertain the stages of esophageal carcinogenesis\[[@B17]-[@B21]\]. Current management guidelines promote endoscopic screening in individuals with esophageal dysplasia, thus it is very important to identify biomarkers to screen high-risk subjects who should undergo endoscopic examination.

The accumulation of p53 protein appears in the very early stage of esophageal carcinogenesis and culminates in malignant transformation, and increased p53 expression observed on immunostaining is associated with a higher risk of histological progression\[[@B22]-[@B27]\]. Carcinoembryonic antigen (CEA) is normally produced during fetal development and is used as a classic tumor marker\[[@B28],[@B29]\]. Carbohydrate antigen sialyl Lewis a (CA19-9) is associated with cancers of the colon, stomach, pancreas and bile duct, but it is also associated with noncancerous conditions\[[@B30]-[@B33]\]. As far as we know there are few studies on CEA and CA19-9 protein expression in biopsy tissue from precancerous lesions of the esophagus in a high-incidence area.

Therefore, we determined whether CEA and CA19-9 protein expression is also related to the early stage of esophageal carcinogenesis transition, whether there are associations between these three biomarkers, and whether the combined expression of these biomarkers may lead to a more thorough understanding of the evolving process of ESCC. The aim was to prove a relationship between the three biomarkers and the stages in the transition to esophageal carcinoma, and to evaluate the combination of these protein biomarkers in predicting the malignant transition of LGD and HGD in an endoscopic screening program.

MATERIALS AND METHODS
=====================

Subjects
--------

An iodine staining endoscopic screening program of esophageal lesions in the high-incidence area of Feicheng County was carried out from January 2004 to December 2007. A questionnaire was used to interview all subjects to obtain basic information. The endoscopic screening test was performed in a small mobile car in villages. For persons with a non-staining area of the mucosa, random 4-quadrant biopsy specimens were obtained. Histopathologic diagnosis was carried out by two pathologists independently. The ethics committee of Shandong Academy of Medical Sciences approved the study protocol and all participants gave their written informed consent.

In this study, subjects with liver diseases and cardiovascular diseases were excluded. Immunohistochemical analysis was performed to determine the expression of p53, CEA and CA19-9 in histological sections of endoscopic biopsies from 603 persons who had free iodine staining regions of the esophagus. Based on pathological diagnosis of the biopsies, BCH was diagnosed in 77 persons, LGD in 247 (mild dysplasia in 167 and moderate dysplasia in 80), HGD in 51 (severe dysplasia in 35 and carcinoma *in situ* in 16), and early invasive carcinoma in 134. Eighty persons had no abnormal lesions and acted as normal controls. The data of 14 persons were excluded from the analysis due to failure of the immunohistochemical test (5 for p53, 4 for CEA and 5 for CA19-9).

Immunohistochemistry
--------------------

The immunohistochemical detection of p53, CEA and CA19-9 proteins was performed using enzyme-linked immunosorbent assay (ELISA) kits (Zymed Laboratories, Inc., South San Francisco, CA, United States).

Reviewing and scoring of the sections
-------------------------------------

The stained sections were reviewed and scored independently by two investigators using an Olympus microscope. Sections stained for p53, CEA and CA19-9 protein expression were scored from 0 to 4: 0, negative (no staining); 1, weakly positive (positive cells were ≤ 10%); 2, positive (positive cells were \> 10% but ≤ 25%); 3, strongly positive (positive cells were \> 25% but ≤ 50%); and 4, very strongly positive (positive cells were \> 50%). In the multinomial logistic model analysis, each biomarker was used as a dependent variable and we defined 0 as negative and 1 as positive in order to avoid a zero number in one or more groups.

Statistical analysis
--------------------

The χ^2^ and Kruskal-Wallis *H* tests were used in the univariate analysis. The Spearman correlation test was performed to determine the association between the three biomarkers. Odds ratios (ORs) were calculated in the multinomial logistic model analysis. Receiver operating characteristic (ROC) curve analysis was used to discriminate the sensitivity and specificity between each lesion group and the normal control group for positive expression of the three biomarkers. All statistical analyses were performed using SPSS (version 17.0), and *P* \< 0.05 (two-sided) was accepted as statistically significant.

RESULTS
=======

p53, CEA and CA19-9 protein expression
--------------------------------------

The univariate analysis indicated that there were significant differences in age, school year, income per year-person, alcohol drinking, and smoking among the five groups, therefore these five variables were adjusted in the multinomial logistic analysis as potential confounding factors. Table [1](#T1){ref-type="table"} shows the characteristics of the variables in the five groups.

###### 

Distribution of selected variables in the esophageal basal cell hyperplasia, low-grade dysplasia, high-grade dysplasia, esophageal squamous cell cancer and control groups^1^ *n* (%)

  **Variables**                                            **ESCC**     **HGD**     **LGD**      **BCH**     **Normal control**
  -------------------------------------------------------- ------------ ----------- ------------ ----------- --------------------
  Gender                                                                                                     
  Male                                                     89 (66.4)    32 (62.7)   146 (59.1)   48 (62.3)   40 (50.0)
  Female                                                   45 (3.6)     19 (37.3)   101 (40.9)   29 (37.7)   40 (50.0)
  Age (yr)                                                                                                   
  40-50                                                    52 (38.8)    16 (31.4)   60 (24.3)    20 (26.0)   7 (8.8)
  50-60                                                    60 (44.8)    25 (49.0)   128 (51.8)   34 (44.2)   29 (36.3)
  ≥ 60                                                     22 (16.4)    10 (19.6)   59 (23.9)    23 (29.9)   44 (55.0)
  School year (yr)                                                                                           
  ≤ 6                                                      79 (59.0)    20 (39.3)   105 (42.5)   32 (41.6)   23 (28.8)
  7-11                                                     50 (37.3)    22 (43.1)   98 (39.7)    30 (39.0)   36 (45.0)
  ≥ 12                                                     5 (3.7)      9 (17.6)    44 (17.8)    15 (19.5)   21 (26.3)
  Income per year-person (\$)                                                                                
  \< 150                                                   60 (44.8)    22 (43.1)   101 (40.9)   26 (33.8)   8 (10.0)
  150-350                                                  56 (41.8)    17 (33.3)   92 (37.2)    24 (31.2)   21 (26.3)
  ≥ 350                                                    18 (13.4)    12 (23.5)   54 (21.9)    27 (35.1)   51 (63.8)
  Family history of esophageal cancer                                                                        
  Yes                                                      19 (14.2)    12 (23.5)   50 (20.2)    16 (20.8)   8 (10.0)
  No                                                       115 (85.8)   39 (76.5)   197 (79.8)   61 (79.2)   72 (90.0)
  Smoking index[2](#T1FN1){ref-type="table-fn"}                                                              
  ≥ 450                                                    52 (38.8)    23 (45.1)   69 (27.8)    31 (40.0)   14 (17.7)
  \< 450                                                   25 (18.7)    4 (7.8)     40 (16.3)    12 (16.0)   16 (20.3)
  None                                                     57 (42.5)    24 (47.1)   138 (55.9)   34 (44.0)   49 (62.0)
  Alcohol drinking index[3](#T1FN2){ref-type="table-fn"}                                                     
  ≥ 120                                                    56 (42.0)    16 (31.4)   77 (31.0)    22 (28.0)   6 (7.5)
  \< 120                                                   28 (20.6)    11 (21.6)   44 (18.0)    17 (22.7)   29 (36.3)
  None                                                     50 (37.4)    24 (47.1)   126 (51.0)   38 (49.3)   45 (56.3)

^1^In the five groups, χ^2^ test values for gender, age, school year, family history of esophageal cancer, income per year-person, smoking index, and alcohol drinking index were 6.046 (*P* = 0.196), 52.858 (*P* \< 0.01), 45.436 (*P* \< 0.01), 76.476 (*P* \< 0.01), 7.137 (*P* = 0.129), 21.682 (*P* = 0.006), and 34.085 (*P* \< 0.01), respectively;

Smoking index = cigarette/day × number of smoking years;

Alcohol drinking ≥ 120 g/d represents heavy drinking. ESCC: Esophageal squamous cell cancer; HGD: High-grade dysplasia; LGD: Low-grade dysplasia; BCH: Basal cell hyperplasia.

The positive rates of p53 protein expression in the ESCC, HGD, LGD, BCH and normal control groups were 53.0%, 52.9%, 35.6%, 27.3% and 20.0%, respectively; the positive rates of CA19-9 protein expression were 44.0%, 33.3%, 16.5%, 9.2% and 6.2%, respectively; the positive rates of CEA protein expression were 74.6%, 60.8%, 23.3%, 23.7% and 16.2%, respectively (Table [2](#T2){ref-type="table"}). The differences in the expression of the three biomarkers in the five groups were significant, and there were also significant linear trends in the increase in positive ratios with the transformation from normal to carcinoma.

###### 

Distribution of p53, CA19-9 and carcinoembryonic antigen expression in the five groups^1^ *n* (%)

  **Protein expression**                                      **ESCC**    **HGD**     **LGD**      **BCH**     **Normal control**
  ----------------------------------------------------------- ----------- ----------- ------------ ----------- --------------------
  p53                                                                                                          
  Negative                                                    63 (47.0)   24 (47.1)   159 (64.4)   56 (72.7)   64 (80.0)
  Positive                                                                                                     
  1%-10%                                                      18 (13.4)   17 (33.3)   62 (25.1)    17 (22.1)   11 (13.8)
  10%-25%                                                     20 (14.9)   8 (15.7)    20 (8.1)     3 (3.9)     5 (6.3)
  25%-50%                                                     24 (17.9)   2 (3.9)     6 (2.4)      1 (1.3)     0 (0)
  ≥ 50%                                                       9 (6.8)     0 (0)       0 (0)        0 (0)       0 (0)
  CA19-9                                                                                                       
  Negative                                                    75 (56.0)   34 (66.7)   206 (83.5)   70 (90.8)   75 (93.8)
  Positive                                                                                                     
  1%-10%                                                      43 (32.1)   15 (29.4)   40 (16.1)    6 (7.9)     4 (5.0)
  10%-25%                                                     13 (9.7)    1 (2.0)     1 (0.4)      0 (0)       1 (1.3)
  ≥ 25%                                                       3 (2.2)     1 (2.0)     0 (0)        1 (1.3)     0 (0)
  CEA                                                                                                          
  Negative                                                    34 (25.4)   20 (39.2)   189 (76.7)   59 (76.3)   67 (83.8)
  Positive                                                                                                     
  1%-10%                                                      47 (35.1)   27 (52.9)   56 (22.5)    16 (21.1)   7 (8.8)
  10%-25%                                                     31 (23.2)   4 (7.8)     2 (0.8)      1 (1.3)     6 (7.5)
  25%-50%                                                     19 (14.2)   0 (0)       0 (0)        1 (1.3)     0 (0)
  ≥ 50%                                                       3 (2.2)     0 (0)       0 (0)        0 (0)       0 (0)
  Three biomarkers combined[2](#T2FN1){ref-type="table-fn"}                                                    
  Negative                                                    21 (15.7)   12 (23.5)   129 (52.4)   44 (57.1)   58 (72.5)
  Positive                                                                                                     
  1%-10%                                                      35 (26.1)   26 (51.0)   90 (36.4)    28 (36.4)   13 (16.3)
  10%-25%                                                     30 (22.4)   10 (19.6)   22 (8.8)     4 (5.2)     9 (11.3)
  25%-50%                                                     36 (26.8)   3 (5.9)     6 (2.4)      1 (1.3)     0 (0)
  ≥ 50%                                                       12 (9.0)    0 (0)       0 (0)        0 (0)       0 (0)

^1^In the five groups, the Kruskal-Wallis *H* test values of the differences in positive protein expression ratios of p53, CA19-9, CEA, and the three biomarkers combined were 50.279 (*P* \< 0.001), 68.660 (*P* \< 0.001), 160.453 (*P* \< 0.001), and 142.393 (*P* \< 0.001), respectively. The values of the linear-by-linear association test were 68.737 (*P* \< 0.001), 61.076 (*P* \< 0.001), 128.738 (*P* \< 0.001), and 141.591 (*P* \< 0.001), respectively;

If the expression of any one of the three biomarkers was positive, the combined expression was counted as positive; if there was an overlap in expression, the score of the strongest expression was taken as the score of the combination. ESCC: Esophageal squamous cell cancer; HGD: High-grade dysplasia; LGD: Low-grade dysplasia; BCH: Basal cell hyperplasia.

The positive rates of the combined expression of the three biomarkers (if the expression of any one of the three biomarkers was positive, the combined expression was counted as positive;if there was an overlap in expression, the score of the strongest expression was taken as the score of the combination) were 84.3%, 76.5%, 47.6%, 42.9% and 27.5% in the five groups, respectively.

Correlations between the three biomarkers and their correlations with other factors
-----------------------------------------------------------------------------------

The correlation coefficients of p53 and CA19-9, p53 and CEA, and CA19-9 and CEA were 0.325, 0.374 and 0.503, respectively (all *P* \< 0.01). The correlation coefficients of p53, CA19-9 and CEA with the degree of esophageal lesions were 0.287, 0.326 and 0.455, respectively (all *P* \< 0.01). Both p53 and CEA, but not CA 19-9, had significant correlations with age (both *P* \< 0.05). The three biomarkers had no significant correlations with school year, alcohol drinking index, smoking index and family history of esophageal cancer (Table [3](#T3){ref-type="table"}).

###### 

The correlation coefficients for p53, CA19-9, CEA and selected variables

  **Variables**                                                  **Spearman\'s correlation coefficient**                                           
  -------------------------------------------------------------- ----------------------------------------- --------------------------------------- ----------------------------------------
  Age                                                            -0.081[1](#T3FN1){ref-type="table-fn"}    -0.065                                  -0.093[1](#T3FN1){ref-type="table-fn"}
  School year                                                    0.197                                     0.139                                   0.213
  Alcohol drinking index                                         -0.050                                    -0.056                                  -0.021
  Smoking index                                                  -0.038                                    -0.050                                  -0.003
  Family history of esophageal cancer                            0.020                                     -0.078                                  -0.035
  Degree of esophageal lesions[3](#T3FN3){ref-type="table-fn"}   0.287[2](#T3FN2){ref-type="table-fn"}     0.326[2](#T3FN2){ref-type="table-fn"}   0.455[2](#T3FN2){ref-type="table-fn"}
  p53                                                            1                                         0.325[2](#T3FN2){ref-type="table-fn"}   0.374[2](#T3FN2){ref-type="table-fn"}
  CA19-9                                                                                                   1.000                                   0.503[2](#T3FN2){ref-type="table-fn"}
  CEA                                                                                                                                              1.000

Correlation is significant at the 0.05 level (2-tailed);

Correlation is significant at the 0.01 level (2-tailed);

The variable definitions for the degree of esophageal lesions were: 1, normal control; 2, basal cell hyperplasia; 3, low-grade dysplasia; 4, high-grade dysplasia; 5, invasive squamous cell cancer.

Relationships of the three biomarkers with the stages of transformation from basal squamous cell hyperplasia to invasive carcinoma
----------------------------------------------------------------------------------------------------------------------------------

The normal control group was regarded as the baseline (OR = 1.0), and both the ORs and 95% CIs of the three biomarkers in the other four groups were calculated using multinomial logistic models. The positive protein expression of p53, CEA and CA19-9 was significantly associated with the four esophageal lesions. As shown in Table [4](#T4){ref-type="table"}, almost all ORs (95%CIs) of p53, CEA and CA19-9 increased with the stages of transition. The strongest relationship was seen in the ESCC group. BCH had no significant association with the positive protein expression of the three biomarkers. However, the combination of the three biomarkers had significant relationships with all four esophageal lesions.

###### 

The associations of the positive expression of p53, CA19-9 and CEA proteins with basal cell hyperplasia, low-grade dysplasia, high-grade dysplasia, and esophageal squamous cell cancer \[OR (95%CI)\]

  **Variables**                                               **ESCC**             **HGD**              **LGD**             **BCH**
  ----------------------------------------------------------- -------------------- -------------------- ------------------- ------------------
  p53                                                                                                                       
  Model 1[1](#T4FN1){ref-type="table-fn"}                     4.51 (2.38-8.59)     4.50 (2.07-9.78)     2.21 (1.21-4.06)    1.50 (0.71-3.15)
  Model 2[2](#T4FN2){ref-type="table-fn"}                     4.52 (2.17-4.92)     4.88 (2.10-11.33)    2.31 (1.17-4.56)    1.60 (0.72-3.57)
  CA19-9                                                                                                                    
  Model 1[1](#T4FN1){ref-type="table-fn"}                     15.15 (7.45-30.84)   7.99 (3.53-18.10)    1.57 (0.81-3.04)    1.60 (0.72-3.54)
  Model 2[2](#T4FN2){ref-type="table-fn"}                     23.57 (9.27-56.86)   12.01 (4.61-31.32)   2.05 (0.91-4.63)    1.99 (0.81-4.93)
  CEA                                                                                                                       
  Model 1[1](#T4FN1){ref-type="table-fn"}                     11.80 (4.49-31.05)   7.50 (2.56-22.00)    2.96 (1.13-7.76)    1.52 (0.46-5.02)
  Model 2[2](#T4FN2){ref-type="table-fn"}                     17.40 (4.76-63.59)   11.06 (2.80-43.71)   3.80 (1.06-13.66)   1.81 (0.41-7.96)
  Three biomarkers combined[3](#T4FN3){ref-type="table-fn"}                                                                 
  Model 1[1](#T4FN1){ref-type="table-fn"}                     14.19 (7.21-27.91)   8.57 (3.80-19.30)    2.40 (1.38-4.15)    1.98 (1.02-3.85)
  Model 2[2](#T4FN2){ref-type="table-fn"}                     16.64 (7.68-36.05)   10.11 (4.20-24.32)   2.59 (1.38-4.86)    2.15 (1.04-4.45)

In the regression model, ORs were calculated without adjustments for any variables;

In the regression model, ORs were calculated after adjustment for age, school year, income per year-person, smoking, alcohol drinking, and family history of esophageal cancer;

If the expression of any one of the three biomarkers was positive, the combined expression was counted as positive; if there was an overlap in expression, the score of the strongest expression was taken as the score of the combination. ESCC: Esophageal squamous cell cancer; HGD: High-grade dysplasia; LGD: Low-grade dysplasia; BCH: Basal cell hyperplasia.

ROC curves and the possibility of predicting the malignant development of the esophageal lesions based on the positive expression of the three biomarkers
---------------------------------------------------------------------------------------------------------------------------------------------------------

In the ROC curve analysis, we used a single biomarker and the combination of the three biomarkers to predict the risk of the four esophageal lesions. As shown in Table [5](#T5){ref-type="table"}, the areas of ROC curves for the combination of the three biomarkers were 0.837, 0.740, 0.590 and 0.562 in the ESCC, HGD, LGD and BCH groups, respectively. Statistical significance was found in the ESCC, HGD and LGD groups, but not in the BCH group.

###### 

Area of receiver operating characteristic curves for p53, CA19-9, CEA and the three biomarkers combined in the four esophageal lesions

  **Protein expression**                                      **Area**   **SE**   **95%CI**      ***Z* value**   ***P* value**
  ----------------------------------------------------------- ---------- -------- -------------- --------------- ---------------
  p53                                                                                                            
  ESCC                                                        0.696      0.0357   0.629-0.756    5.483           0.001
  HGD                                                         0.669      0.0495   0.581-0.749    3.416           0.006
  LGD                                                         0.578      0.0356   0.523-0.632    2.197           0.028
  BCH                                                         0.533      0.0461   0.452-0.613    0.725           0.468
  CA19-9                                                                                                         
  ESCC                                                        0.650      0.0359   0.625-0.751    5.288           \< 0.001
  HGD                                                         0.638      0.0509   0.549-7.200    2.714           0.007
  LGD                                                         0.554      0.0363   0.498-0.609    1.484           0.138
  BCH                                                         0.515      0.0464   0.433-0.595    0.317           0.751
  CEA                                                                                                            
  ESCC                                                        0.802      0.0293   0.742-0.853    10.302          \< 0.001
  HGD                                                         0.712      0.0479   0.260-0.788    4.423           \< 0.001
  LGD                                                         0.532      0.0369   0.476-0.558    0.872           0.383
  BCH                                                         0.531      0.0463   0.449-0.611    0.668           0.504
  Three biomarkers combined[1](#T5FN1){ref-type="table-fn"}                                                      
  ESCC                                                        0.837      0.0260   0.780-0.884    212.656         \< 0.001
  HGD                                                         0.740      0.0460   0.656-0.813    5.220           \< 0.001
  LGD                                                         0.590      0.0352   0.535-0.644    2.586           0.010
  BCH                                                         0.562      0.0458   0.0481-0.641   1.360           0.174

If the expression of any one of the three biomarkers was positive, the combined expression was counted as positive; if there was an overlap in expression, the score of the strongest expression was taken as the score of the combination. ESCC: Esophageal squamous cell cancer; HGD: High-grade dysplasia; LGD: Low-grade dysplasia; BCH: Basal cell hyperplasia.

When the positive expression score of 10%-25% was taken as the cut-off value, the sensitivities and specificities of the four ROC curves were determined and are shown in Table [6](#T6){ref-type="table"} and Figure [1](#F1){ref-type="fig"}. In the ROC curves of the combination of the three biomarkers, the specificity was 88.8% for the normal control group, the sensitivity was 58.2% for the ESCC group, 25.5% for the HGD group, 11.2% for the LGD group, and 6.5% for the BCH group.

![Curves for predicting esophageal lesions based on positive expression of the three biomarkers. These ROC curves are for ESCC (A), HGD (B), LGD (C), and BCH (D), respectively. Note: If the expression of any one of the three biomarkers was positive, the combined expression was counted as positive; if there was an overlap in expression, the score of the strongest expression was taken as the score of the combination. ESCC: Esophageal squamous cell cancer; HGD: High-grade dysplasia; LGD: Low-grade dysplasia; BCH: Basal cell hyperplasia; ROC: Receiver operating characteristic curve.](WJG-22-8770-g001){#F1}

###### 

Diagnostic values of predicting the four esophageal lesions based on the positive expression of the three biomarkers combined at the cut off value of 10%-25%^1^ (%)

  **Group**   **Sensitivity**   **95%CI**   **+PV**   **95%CI**
  ----------- ----------------- ----------- --------- -----------
  ESCC        58.2              49.4-66.7   89.7      81.3-95.1
  HGD         25.5              14.3-39.6   59.1      36.4-79.3
  LGD         11.2              7.6-15.8    75.7      58.8-88.2
  BCH         6.5               2.2-14.5    35.7      12.9-64.8

^1^If the expression of any one of the three biomarkers was positive, the combined expression was counted as positive; if there was an overlap in expression, the score of the strongest expression was taken as the score of the combination. The specificity was 88.8% for the normal control group, with a 95%CI of 79.7%-94.7%. ESCC: Esophageal squamous cell cancer; HGD: High-grade dysplasia; LGD: Low-grade dysplasia; BCH: Basal cell hyperplasia.

DISCUSSION
==========

Wild-type p53 suppresses cell proliferation in normal tissues\[[@B34]\], and p53 overexpression is regarded as a potential tumor prognostic factor\[[@B35]-[@B39]\]. Increased p53 expression in the pathogenesis of ESCC or adenocarcinoma indicates that p53 overexpression is involved in the initial steps of esophageal carcinogenesis and contributes to the development of precancerous lesions. van Dekken et al\[[@B40]\] studied histologic sections of endoscopic biopsies from patients with Barrett's esophagus, and found a significant trend for p53 protein overexpression during malignant progression. Kim et al\[[@B23]\] reported that positively stained p53 protein was observed in 87% of ESCC, 80% of esophageal dysplasia, and was not observed in normal mucosa. Bellini et al\[[@B26]\] reported that positive p53 immunohistochemistry progressively increased with pathology severity: Chagas disease (7.7%), chagasic megaesophagus (26.1%), chronic esophagitis (52.2%) and ESCC (100%). We also found that p53 expression showed a significant linear trend with the transition from normal to cancer.

An increase in CEA or CA19-9 level is associated with a more advanced tumor stage\[[@B32],[@B41]\], and their combination may provide more information for diagnosis and prognosis. Bagaria et al\[[@B42]\] reported that with the specificity set at 100%, the sensitivity for esophageal cancer was 28%, 18% and 42% for CEA, CA19-9 and their combination, respectively. Scarpa et al\[[@B43]\] reported that the two biomarkers should be considered when evaluating candidates for esophagectomy.

Setoyama et al\[[@B44]\] found that CEA mRNA expression was positively related to tumor depth and lymph node metastasis in ESCC patients. In another study, CEA mRNA was expressed in the blood, even though CEA and CA19-9 were normal in patients with relapse\[[@B45]\]. From these studies, we suggest that the serum level of CEA or CA19-9 protein expression in patients with early stages of carcinoma may be too low to be detected. In contrast, CEA or CA19-9 protein expression in biopsies from patients with the initial stages of esophageal carcinogenesis can easily be detected by immunohistochemistry. In the present study, the main finding was that the positive expression of CEA and CA19-9 proteins increased with the severity of BCH, dysplasia and carcinoma of the esophagus. These results are useful in understanding the mechanism of the evolution of esophageal cancer at the molecular level of protein expression.

Positive protein expression of p53, CEA and CA19-9 was associated with esophageal carcinogenesis, and a moderate association was found between the three biomarkers in the present study. Interestingly, we discovered that when the positive expressions of the three biomarkers were combined, the specificity for diagnosis of esophageal lesions was 88.8%, which was the target level for screening high-risk individuals, and the sensitivities markedly increased with severity of the esophageal lesions.

However, the identification of patients with dysplasia who will then develop malignant lesions is very important. It is known that p53, CA19-9 and CEA proteins are secreted by malignant cells, and the simultaneous positive expression of these biomarkers in benign pathological lesions of the esophagus may possibly indicate that these lesions will become malignant. Our results indicate that an endoscopic screening program to detect these three biomarkers is beneficial to identify high-risk individuals with esophageal diseases. This information will be useful for doctors to plan the follow-up interval for endoscopic biopsy surveillance, and to decide on appropriate treatment.

It is difficult to obtain a biopsy from the free iodine staining area exactly at the site of the lesion, thus there may be some misclassification of diagnosis, and the controls may not have normal esophageal mucosa. Therefore, the expression rates of the three biomarkers were much higher in the controls. It is possible that the predictive values of the three biomarkers for the stages of ESCC may have been underestimated.

In addition, the expression of other biomarkers, such as p21\[[@B46]\], Ki-67, ProExC\[[@B47]\] and cyclin D1\[[@B48]\], is associated with ESCC, thus the relatively low sensitivity of the three biomarkers combined in the present study may have been influenced by other mechanisms involved in ESCC carcinogenesis.
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Background
----------

Esophageal squamous cell carcinoma (ESCC) is one of the most lethal malignancies, and the pathogenesis involves a stepwise progression from basal cell hyperplasia (BCH) to low-grade dysplasia (LGD), high-grade dysplasia (HGD), carcinoma *in situ*, and finally invasive carcinoma. It is very important to identify biomarkers to screen high-risk subjects.
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